Search results
The race for a weight loss pill heats up as a Novo Nordisk competitor releases new trial results
Quartz· 1 day agoA small clinical study found that patients taking a daily dose of Structure’s experimental weight ...
Structure Therapeutics (GPCR) Stock Soars 60% on Weight Loss Drug Success
InvestorPlace· 1 day agoStructure Therapeutics (NASDAQ:GPCR) stock is surging today, up 60% after the biotech company...
William Blair Commentary: Waistlines and GLP1-s--Expanding in Unison
GuruFocus.com via Yahoo Finance· 10 hours agoGiven the significant TAM of GLP-1 medications...make any inroads given the time it takes to bring...
Structure Therapeutics Stock Soars on Obesity Pill Data
The Wall Street Journal· 1 day agoStructure’s once-daily drug, code-named GSBR-1290, helped people lose an average of more than 6% of...
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
Motley Fool via Yahoo Finance· 4 days agoNovo Nordisk and Eli Lilly are the early leaders in the GLP-1 weight loss market, but that may not...
Shape's Dietary Supplement Methodology
Shape via Yahoo News· 7 hours agoWe scrutinize ingredients in these products carefully and dig into the research to see if there’s real beauty benefit. ...beyond the typical risks...
France against Servier selling generics unit Biogaran, PM says
Reuters via AOL· 7 days agoPARIS (Reuters) -The French government has told drugmaker Servier it is against any sale of its...
For those who wished for "a magic fix" for weight loss, Ozempic craze can trigger complicated...
CBS News· 4 days agoWhile research has looked at the potential mental health impact of taking semaglutide drugs like...
CNBC Daily Open: GameStop can't stop, Dow drops
CNBC· 20 hours agoA screen displays the logo and trading information for GameStop on the floor of the New York Stock Exchange. This report is from today's CNBC Daily Open,...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 5 days agoAstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as...
